<DOC>
	<DOCNO>NCT02600130</DOCNO>
	<brief_summary>This Phase I , prospective , randomize , placebo-controlled , double-blinded study design test safety efficacy LMSCs ( Longeveron Mesenchymal Stem Cells ) treatment subject clinically diagnose Alzheimer 's disease .</brief_summary>
	<brief_title>Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>This randomize , placebo-controlled clinical trial design evaluate safety efficacy LMSCs ( Longeveron Mesenchymal Stem Cells ) placebo subject Alzheimer 's Disease . Following successful Safety Run-In Phase , total twenty-five ( 25 ) subject randomize ( 2:2:1 ) receive low-dose LMSCs , high-dose LMSCs placebo . After randomization , baseline imaging , study product infusion , subject follow 2,4,13,39 52 week post study product infusion . Intention-to-treat study population use purpose endpoint analysis safety evaluation .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>All subject enrol trial must : provide write informed consent ; 50 80 year age time sign Informed Consent form ; body mass 45 150 kg . time enrollment , diagnose AD accordance NINCDSAA criterion ; score 18 24 Mini Mental State Examination ( MMSE ) ; one ( ) identify adult caregiver willing provide write informed consent his/her participation ; able read , understand , speak designate language study site ; either live subject see subject ≥2 hours/day ≥3 days/week ; agree accompany subject study visit . blood oxygen saturation ≥93 % determined via pulse oximetry . brain MRI consistent AD ; PET scan use FDAapproved tracer ( e.g. , AMYViD , Vizamyl , Neuraceq ) , indicate presence betaamyloid plaques cerebral cortex , within 5 year enrollment ; normal level thyroid hormone ( free T4 ) thyroidstimulating hormone ( TSH ) ; normal level B12 folate ; use acetylcholinesterase inhibitor and/or Memantine treatment stable dosage least 4 month prior screen ; designate study partner accompany subject clinic visit participate subject 's clinical assessment ; live community , include assist living facility , exclude longterm care nursing facility . negative hepatitis B HsAg , viremic hepatitis C , HIV . All subject enrol trial must : unable perform assessment require endpoint analysis ; show sign dementia AD , AIDS ( Acquired Immunodeficiency Syndrome ) , CJD ( CreutzfeldtJakob disease ) , LBD ( Lewy Bodies dementia ) , CVD ( Cerebrovascular dementia ) , PSP ( Progressive Supranuclear Palsy ) , MCI ( multiple cerebral infarction ) NPH ( normal pressure hydrocephalus ) ; neurodegenerative disease ; history seizure disorder ; clinically important abnormal screen laboratory value beyond AD ; condition would contraindicate MRI , presence metallic object eye , skin , heart ; condition would contraindicate PET scan ; &gt; 4 cerebral microhemorrhages ( regardless anatomical location diagnostic characterization `` possible '' `` definite '' ) , single area superficial siderosis , evidence prior macrohemorrhage assess MRI ; currently use corticosteroid similar powerful steroidal antiinflammatory medication ( e.g. , Prednisone ) regular basis ( exception allow include regular use steroidal nasal spray , topical steroid , estrogenreplacement therapy ) ; active list ( expect list ) transplant organ ; organ transplant recipient ; know hypersensitivity dimethyl sulfoxide ( DMSO ) . condition project limited life expectancy &lt; 1 year . sit rest systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg Screening ; Have history alcohol drug abuse within past 5 year . diagnosed malignancy within past 5 year , exception curativelytreated basal cell carcinoma , squamous cell carcinoma , melanoma situ cervical carcinoma ; female FSH &lt; 25.8 IU/L ; female pregnant , nursing , childbearing potential ( defined Section 9.2.2 ) practice effective contraception ( female subject must undergo urine pregnancy test screen infusion day prior infusion ) ; serious illness condition , opinion investigator , may compromise safety compliance subject preclude successful completion study ; serious illness condition , opinion investigator , may compromise validity study ( e.g. , sign stroke , traumatic brain injury ( TBI ) , multiple sclerosis ( MS ) , amyotrophic lateral sclerosis ( ALS ) , Parkinsonism ) ; participate investigational therapeutic device trial within past 5 year investigator feel would influence affect outcome study ; Be currently participate ( participate within previous 30 day ) investigational therapeutic device trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>